PALT02

Post-marketing clinical trial of Pemafibrate in patients with impaired renal function

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200177

Enrollment

Registered

2020-10-28

Start date

2020-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslidemia

Interventions

0.1mg, twice a day, oral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Dyslidemia : Fasting Serum TG>=150mg/dL 2) Renal dysfunction (A:eGFR<30mL/min/1.73m^2, B:Hemodialysis, C:30<=eGFR<60mL/min/1.73m^2)

Exclusion criteria

Exclusion criteria: 1) Patients with severe liver damage, cirrhosis or biliary atresia patient 2) Patients with gallstones 3) Pregnant women or women who may be pregnant 4) Patients who have had a kidney transplant

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameter (AUC)	—

Contacts

Public ContactYukihisa Sogabe

Kowa Company, Ltd.

ctrdinfo@kowa.co.jp+81-3-3279-7454

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026